admin

The Indian currency has lost over 0.9% value against the US dollar by the second trading day of the week.

Samsung has allegedly held preliminary discussions with lenders but is yet to make a decision regarding proceeding with the same, people in the know told Bloomberg.

The partnership combines Formycon’s biosimilar development capabilities with OneSource’s end-to-end biologics manufacturing platform to support Formycon’s global biosimilar pipeline.

The brokerage said Saatvik Green is well placed to benefit from the rapid growth in India’s solar manufacturing industry, supported by its ongoing capacity expansion and backward integration plans.

Between financial year 2026-2029, Investec expects Seshaasai Technologies’ revenue to grow at a Compounded Annual Growth Rate (CAGR) of close to 12%, while Profit After Tax (PAT) could outperform its topline, with a 14% CAGR over the same timeframe.

EXIM container volumes rose 9.8% to 10,69,082 TEUs from 9,73,875 TEUs a year earlier, while domestic container volumes increased 6.2% to 3,35,739 TEUs from 3,16,226 TEUs.

Just Dial ended the quarter with nearly ₹6,022 crore of cash and investments, exceeding its market capitalisation of about ₹5,600 crore. Brokerages Kotak and Citi said the key trigger going forward will be how the new management deploys this cash,…

Alembic Pharmaceuticals said the warning letter relates to a clinical investigator involved in a study carried out at Alembic’s bioequivalence facility in Vadodara. The company became aware of the communication on July 12.

IDBI Bank disinvestment cleared. Government and LIC to sell 60.72% stake, transferring management control. Strategic sale moves forward.

Mylan was offered a 6% stake in Biocon after the Biocon Biologics deal, in which Biocon had acquired all of Mylan’s stake in the Biologics unit in January this year through a share swap and cash.